 Connection
Matteus Krappitz to Polycystic Kidney Diseases
This is a "connection" page, showing publications Matteus Krappitz has written about Polycystic Kidney Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.057 |
|
|
|
-
Krappitz M, Bhardwaj R, Dong K, Staudner T, Yilmaz DE, Pioppini C, Westergerling P, Ruemmele D, Hollmann T, Nguyen TA, Cai Y, Gallagher AR, Somlo S, Fedeles S. XBP1 Activation Reduces Severity of Polycystic Kidney Disease due to a Nontruncating Polycystin-1 Mutation in Mice. J Am Soc Nephrol. 2023 01 01; 34(1):110-121.
Score: 0.708
-
Fedeles BI, Bhardwaj R, Ishikawa Y, Khumsubdee S, Krappitz M, Gubina N, Volpe I, Andrade DC, Westergerling P, Staudner T, Campolo J, Liu SS, Dong K, Cai Y, Rehman M, Gallagher AR, Ruchirawat S, Croy RG, Essigmann JM, Fedeles SV, Somlo S. A synthetic agent ameliorates polycystic kidney disease by promoting apoptosis of cystic cells through increased oxidative stress. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2317344121.
Score: 0.193
-
Vien TN, Ng LCT, Smith JM, Dong K, Krappitz M, Gainullin VG, Fedeles S, Harris PC, Somlo S, DeCaen PG. Disrupting polycystin-2 EF hand Ca2+ affinity does not alter channel function or contribute to polycystic kidney disease. J Cell Sci. 2020 12 24; 133(24).
Score: 0.156
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|